Astellas Pharma Inc. badly wanted to expand its rights to FibroGen Inc. 's oral anemia compounds beyond Japan. So badly, in fact, that it paid a whopping $300 million up front, agreed to up to $465 million in pre-approval milestones, and will fund half of the compounds' development in Europe and North America. [See Deal] Yet Astellas doesn't even get North American commercial rights in exchange: it had to settle for European and other ex-US territories.
Even so, the Japanese pharma had to fight hard to win the deal. There were plenty of bigger Big Pharmas...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?